-
Sobi Announces Borje Ekholm as Proposed New Chair of the Board
A New Chapter for Sobi’s Leadership Swedish Orphan Biovitrum AB (Sobi) has officially announced a significant development in its corporate governance. The company’s Nomination Committee has proposed Borje Ekholm as the new Chair of the Board of Directors, signaling a strategic move to strengthen the leadership team as the organization continues to grow. Who is…
-
A Tiny Fish, A Huge Breakthrough: Mapping Gene Activity in Vertebrates
The ZFIN Map: A Milestone in Genetics For years, scientists have sought to understand how genes work in unison across an entire complex organism. Now, a groundbreaking study involving the zebrafish (Danio rerio) has provided the first-ever full-body map of gene activity in an adult vertebrate. This research marks a transformative moment for developmental biology…
-
Azenta Prepares to Reveal Fiscal 2026 Financial Results
NASDAQ: $AZTA Mark Your Calendars for Azenta’s Fiscal Year-End Update Azenta, Inc. (Nasdaq: AZTA) has officially scheduled its conference call and webcast to discuss the company’s financial results for the fourth quarter and full fiscal year 2026. This event is a critical touchpoint for investors and stakeholders to gain insight into the company’s performance and…
-
Huntington’s Disease Foundation Commits $2 Million for its 2026 Transformative Research Awards
Two innovative research projects will pursue distinct strategies to advance potential treatments for Huntington’s disease. NEW YORK, Oct. 28, 2026 /PRNewswire/ — The Huntington’s Disease Foundation (HDF) has awarded $2 million for its 2026 Transformative Research Awards (TRAs) to support… Source: Read More
-
A Breakthrough in Endometrial Cancer: New Chemotherapy-Free Treatment Shows Promise
A Shift in Cancer Care A landmark global Phase 3 clinical trial, led by a physician at Mount Sinai Medical Center, has unveiled encouraging results for patients with dMMR (mismatch repair deficient) endometrial cancer. The study demonstrates that a chemotherapy-free treatment regimen can significantly improve outcomes, marking a potential turning point in how this gynecological…
-
Understanding Inducement Grants: A Look at Nektar Therapeutics’ Recent Disclosure
NASDAQ: $NKTR What Are Inducement Grants? In the world of corporate governance, transparency is key. Recently, Nektar Therapeutics (NASDAQ: NKTR) issued a formal report regarding the granting of equity awards to new employees. These types of transactions are often referred to as inducement grants. The Details Behind the Disclosure On August 29, 2019, Nektar Therapeutics…
-
New Treatment Option: FDA Approves Subcutaneous Induction for Skyrizi in Crohn’s Disease
NYSE: $ABBV A New Milestone in Crohn’s Disease Management For adults living with moderately to severely active Crohn’s disease, there is a significant new development in treatment accessibility. The U.S. Food and Drug Administration (FDA) has officially approved a subcutaneous (SC) induction regimen for AbbVie’s Skyrizi (risankizumab-rzaa). What This Means for Patients Previously, patients often…
-
Advancing AAT Deficiency Treatment: Congruence Therapeutics Presents CGX-195
A New Frontier in AAT Deficiency Congruence Therapeutics has reached a significant milestone in its pursuit of novel therapies for Alpha-1 Antitrypsin (AAT) deficiency. The company recently announced that it will provide an oral presentation on its lead program, CGX-195, at the prestigious ERS Alpha-1 Antitrypsin (AAT) Conference 2026. Understanding CGX-195 CGX-195 is being developed…
-
ImmunoForge Sets the Stage for Innovation at BIO-Europe 2026
Advancing the Future of Oncology As the global biotech community prepares for the upcoming BIO-Europe 2026 conference, ImmunoForge has announced its intention to showcase significant advancements in its therapeutic portfolio. The company is set to present its proprietary platform technologies and share critical updates regarding its next-generation oncology research and development efforts. Focusing on Clinical…
-
A New Frontier in Cancer Therapy: GeorgiaMune and Menarini Join Forces
A Strategic Partnership in Immuno-Oncology The landscape of cancer treatment is evolving rapidly, and a recent announcement highlights a significant step forward. GeorgiaMune, a biotechnology company focused on innovative medical solutions, has entered into an exclusive global licensing and collaboration agreement with the Menarini Group. This partnership centers on the development of GIM-621, a promising…
-
HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial
Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27% Median progression-free survival was 11.7 months… Source: Read More
-
Phylo’s Biomni Lab to expand the use of AI agents in scientific research at Bayer
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 /PRNewswire/ — Phylo, Inc. announced today a partnership with Bayer to deploy Biomni Lab, Phylo’s agentic AI platform to accelerate scientific research and evaluation. Under the agreement, Phylo will provide Bayer with full access to its agentic… Source: Read More
-
Vanda Pharmaceuticals Sets Date for Q3 2026 Financial Results
NASDAQ: $VNDA Mark Your Calendars: Q3 2026 Financial Update Vanda Pharmaceuticals Inc. has officially announced that it will release its financial results for the third quarter of 2026 on Wednesday, October 28, 2026. This upcoming disclosure is a key event for investors and stakeholders looking to gauge the company’s performance throughout the quarter. How to…
-
Fresenius Medical Care Enhances Critical Care with the U.S. Launch of multiFiltratePRO
A New Standard in Intensive Care Kidney Support Fresenius Medical Care, a global leader in renal care, has officially announced the U.S. launch of the multiFiltratePRO. This innovative system is designed to provide life-sustaining kidney replacement therapy for patients in critical care settings, marking a significant advancement in how hospitals manage acute kidney injury (AKI).…
-
Genomma Lab Internacional Announces Results for the Third Quarter 2026
MEXICO CITY, Oct. 21, 2026 /PRNewswire/ — Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma” or “the Company”), today announced its results for the third quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with… Source: Read More
-
Early LGS-CORE Registry Data Show Only 4% of Reported Treatments Stopped All Seizures in Lennox-Gastaut Syndrome
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ — The Lennox-Gastaut Syndrome (LGS) Foundation will present the first data from its LGS Collaborative Outcomes Registry (LGS-CORE) at the 2026 NORD Rare Diseases & Orphan Products Breakthrough Summit, October 25 to 27 in Washington, DC. LGS-CORE is a… Source: Read More
-
Trinity Acquires Verix, Adding AI-Powered Next-Best-Action and Omnichannel Orchestration to the TrinityEDGE Platform
Verix’s patented Tovana™ platform and its full team join Trinity, extending TrinityEDGE™ from what commercial teams know into what they do next WALTHAM, Mass., Oct. 20, 2026 /PRNewswire/ — Trinity, the leader in integrating human and artificial intelligence for life sciences… Source: Read More
-
Myosin Therapeutics Invited to Present at BioFuture 2026 in New York City
JUPITER, Fla., Oct. 16, 2026 /PRNewswire/ — Myosin Therapeutics today announced that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives Showcase Company, it has been invited to present at BioFuture 2026, taking place October 27–28 in New… Source: Read More
-
Westcove Advises Clinical Research of West Florida in its Partnership with Fengate Private Equity
LOS ANGELES, Oct. 16, 2026 /PRNewswire/ — Westcove Partners, LLC (“Westcove”), a highly specialized investment bank, announced that it acted as the exclusive financial advisor to Clinical Research of West Florida (“CRWF”) in its partnership with Fengate Private Equity, a division of… Source: Read More
-
The Future of Oncology: Cancer Diagnostics Market Poised to Hit $41.5 Billion by 2031
A Significant Shift in Healthcare The landscape of oncology is undergoing a profound transformation. According to recent findings from Wissen Research, the global cancer diagnostics market is on a trajectory of rapid expansion. Valued significantly today, the industry is projected to reach an impressive US $41.5 billion by 2031. Growth Drivers This projected growth reflects…
-
Atomvie Global Radiopharma and Jubilant Radiopharma Announce Strategic Partnership for Clinical Logistics
Strengthening the Future of Radiopharmaceutical Distribution In a significant move for the field of nuclear medicine, Atomvie Global Radiopharma has officially announced a strategic partnership with Jubilant Radiopharma. This collaboration is designed to optimize and expand the logistics and distribution network for clinical trials, addressing the complex supply chain challenges inherent in radiopharmaceutical development. Strategic…
-
Bold Therapeutics Hits Key Milestone in Phase 2 Trial for Metastatic Colorectal Cancer
A Significant Step Forward in Cancer Research Bold Therapeutics has officially announced a major achievement in its clinical development program: the company has reached the enrollment midpoint for its randomized Phase 2 clinical trial evaluating BOLD-100. This trial is specifically focused on patients battling second-line metastatic colorectal cancer (mCRC). Understanding the Potential of BOLD-100 BOLD-100…
-
NICHOLSMD Brings Advanced Hair Restoration to Greenwich with ACORN-YOU Secretome
Revolutionizing Hair Health in Greenwich NICHOLSMD of Greenwich has officially announced the launch of ACORN-YOU Secretome, a groundbreaking treatment now available at The Hair Lab. This innovative therapy represents a significant shift in regenerative aesthetics, focusing on the power of secretome technology to address hair thinning and loss. What is ACORN-YOU Secretome? The ACORN-YOU Secretome…
-
Paradigm Therapeutics Recognized Again: SD-101 Nominated for Prestigious Prix Galien USA 2026
A Repeat Achievement in Biotech Innovation Paradigm Therapeutics Inc. has once again solidified its position at the forefront of medical innovation. For the second consecutive year, the company has been nominated for the highly esteemed Prix Galien USA 2026. This recognition highlights the company’s commitment to pushing the boundaries of dermatological science. The Innovation: SD-101…